Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

Solaymani-Dodaran
 
IRCT20200318046812N1
RCTfavipiravir lopinavir/ritonavirCOVID-19 mild to moderatesome concern
193/187 inconclusive
    ELACOI (Lopinavir/ritonavir)
     
    NCT04252885
    RCTumifenovir (arbidol)lopinavir/ritonavirCOVID-19 mild to moderatesome concern
    35/34 inconclusive
    • inconclusive 84 % increase in viral clearance by day 14 (PE) with a moderate degree of certainty due to some concern in risk of bias
    • inconclusive 8 % increase in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
    Hung et al.
     
    NCT04276688
    RCTlopinavir/ritonavir, ribavirin and interferon beta-1blopinavir/ritonavirCOVID-19 mild to moderatesome concern
    86/41 conclusif
    • demonstrated 3.4-fold increase in viral clearance ,viral clearance (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 2.9-fold increase in clinical improvement,clinical improvement (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
    1 study excluded by filtering options (1 RCT / 0 OBS)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).